Pressure BioSciences (Pressure BioSciences) Change In Working Capital : $3.15 Mil (TTM As of Sep. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Pressure BioSciences Change In Working Capital?

Pressure BioSciences's change in working capital for the quarter that ended in Sep. 2023 was $0.73 Mil.

Pressure BioSciences's change in working capital for the fiscal year that ended in Dec. 2022 was $3.02 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Pressure BioSciences Change In Working Capital Historical Data

The historical data trend for Pressure BioSciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pressure BioSciences Change In Working Capital Chart

Pressure BioSciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

0.61

1.42

4.03

0.20

3.02

Pressure BioSciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Working Capital	Get a 7-Day Free Trial															1.14	0.88	0.72	0.81	0.73

Pressure BioSciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.15 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Pressure BioSciences Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Pressure BioSciences's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pressure BioSciences (Pressure BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pressure BioSciences Inc (OTCPK:PBIO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

14 Norfolk Avenue, South Easton, MA, USA, 02375

Website

https://www.pressurebiosciences.com

Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.

Executives

Daniel Joseph Shea	officer: Senior Vice President & CFO	2 MINUTEMAN ROAD, MEDFIELD MA 02052
Bradford Addison Young	officer: Chief Commercial Officer	513 LITTLE JOHN HILL, ANNAPOLIS MD 21405
Richard T Schumacher	director, officer: Chief Executive Officer	375 WEST STREET, WEST BRIDGEWATER MA 02379
Nathan Lawrence	other: VP Sales and Marketing	321 MANLEY STREET, WEST BRIDGEWATER MA 02379
Richard Thomley	officer: Chief Financial Officer	C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375
Kevin Pollack	director	150 RAINVILLE ROAD, TARPON SPRINGS FL 34689
Michael S Urdea	director	100 BUNCE MEADOWS DRIVE, ALAMO CA 94507
Alexander V Lazarev	officer: VP of REsearch and Development	18 WINCHESTER DRIVE, LEXINGTON MA 02420
Edmund Y Ting	officer: Senior VP of Engineering	23642 123RD PLACE SOUTHEAST, KENT WA 48031
Vito J Mangiardi	director	12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903
Jeffrey N Peterson	director	1031 SHORELINE DRIVE, SAN MATEO CA 94404
Mir Conrad F	officer: CFO	19 BRIER LANE, CLIFTON NJ 07012
Clayton A Struve	10 percent owner	175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604
Css Llc/il	other: (a)	175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604
R Wayne Fritzsche	director	835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067